SPECIALLY COLLECTED PAPERS
Using a Microchip-based DNA analyzer “MultiNATM”
Shimadzu Review 78[3・4] (2021)
Glycans attached to antibody therapeutics are an important quality attribute for controlling the production of antibody therapeutics. To monitor N-glycosylation in recombinant proteins, a high-throughput (HTP) methodology is required to analyze bulk samples in the manufacturing process. The MultiNA™ microchip electrophoresis system for DNA/RNA analysis is probably the only separation analysis system capable of analyzing multiple samples in a semiparallel manner and providing HTP glycan screening. In this article, we describes a microchip electrophoresis-based HTP N-glycan screening of antibody therapeutics using the MultiNA™. The developed method was also applied to analyze various antibody therapeutics. Major biantennary glycans unique to antibodies (G0F, G1F, G1F`, and G2F) as well as sialoglycans and αGal-containing glycans were successfully separated and detected, making this a promising analytical technique for implementing a Quality by Design (QbD) approach while controlling the production process using glycans as Critical Quality Attributes (CQA).
1Department of Pharmaceutical Sciences, Kindai University, 3-4-1, Kowakae, Higashi-osaka, Japan
2Global Application Development Center, Analytical & Measuring Instruments Division, Shimadzu Corporation, Kyoto, Japan
3AcroScale Inc., 468-1, Aramakiaza Aoba, Aoba-ku, Sendai, Japan
*The information contained in Shimadzu Review has not been modified since the original publication date. Please be aware that in some cases, products mentioned within the articles are no longer available.